CN106616602A - Preparation method of black Chinese wolfberry fruit probiotic tablets - Google Patents
Preparation method of black Chinese wolfberry fruit probiotic tablets Download PDFInfo
- Publication number
- CN106616602A CN106616602A CN201611130168.XA CN201611130168A CN106616602A CN 106616602 A CN106616602 A CN 106616602A CN 201611130168 A CN201611130168 A CN 201611130168A CN 106616602 A CN106616602 A CN 106616602A
- Authority
- CN
- China
- Prior art keywords
- powder
- parts
- lycium ruthenicum
- raw material
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 63
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 63
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 title abstract description 8
- 244000241872 Lycium chinense Species 0.000 title abstract 6
- 235000015468 Lycium chinense Nutrition 0.000 title abstract 6
- 239000000843 powder Substances 0.000 claims abstract description 76
- 239000002994 raw material Substances 0.000 claims abstract description 53
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 33
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000000811 xylitol Substances 0.000 claims abstract description 33
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 33
- 235000010447 xylitol Nutrition 0.000 claims abstract description 33
- 229960002675 xylitol Drugs 0.000 claims abstract description 33
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 19
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 17
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 17
- 239000011648 beta-carotene Substances 0.000 claims abstract description 17
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 17
- 229960002747 betacarotene Drugs 0.000 claims abstract description 17
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 14
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 13
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 13
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 13
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 13
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 6
- 235000001727 glucose Nutrition 0.000 claims abstract description 6
- 229960001031 glucose Drugs 0.000 claims abstract description 6
- 241000169546 Lycium ruthenicum Species 0.000 claims description 50
- 239000002245 particle Substances 0.000 claims description 41
- 241000894006 Bacteria Species 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 16
- 229940116298 l- malic acid Drugs 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 16
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 235000011090 malic acid Nutrition 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract 3
- 235000018927 edible plant Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 61
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 235000013305 food Nutrition 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 235000014347 soups Nutrition 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000021049 nutrient content Nutrition 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 235000008935 nutritious Nutrition 0.000 description 3
- 238000005453 pelletization Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 244000141359 Malus pumila Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000675 anti-caries Effects 0.000 description 2
- 235000021016 apples Nutrition 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- BPHVHMBNGQRCNN-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;potassium Chemical compound [K].OC(=O)C(O)C(O)C(O)=O BPHVHMBNGQRCNN-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020575 Hyperammonaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000227425 Pieris rapae crucivora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 150000001453 anthocyanidins Chemical class 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940070017 potassium supplement Drugs 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Abstract
The present method discloses a preparation method of black Chinese wolfberry fruit probiotic tablets. Black Chinese wolfberry fruit powder, galactooligosaccharide, glucose, microcrystalline cellulose, xylitol, beta-carotene and L-malic acids are used as raw materials, the raw materials are mixed to conduct granulation, and granules are screened to obtain raw material granules. Bifidobacterium lactis V9 powder, lactobacillus plantarum P-8 powder and lactobacillus casei Zhang are used as the raw materials, and the materials are mixed to prepare probiotic powder. The raw material granules and the probiotic powder are mixed to obtain tableting raw materials. The tableting raw materials are tableted by using a tableting machine to obtain the black Chinese wolfberry fruit probiotic tablets. The purely medicinal and edible plants are used as the raw materials, the probiotics beneficial to human body health are matched to obtain the tablets, and the tablets are free of any toxic and side effects, easy to absorb and use, strong in activity, easy to take, can significantly improve the absorption and utilization of the nutrients of the black Chinese wolfberry fruits, and enhance the health-care effects of the black Chinese wolfberry fruits.
Description
Technical field
The present invention relates to functional health-care food field, more particularly to a kind of preparation method of lycium ruthenicum probiotics tablets.
Background technology
Lycium ruthenicum is sweet, mild-natured, rich in anthocyanidin, protein, fat, carbohydrate, free amino acid, organic acid, mineral matter,
Trace element, alkaloid and the various nutrient contents such as vitamin C, B1, B2.
Probio can adjust the balance of human body intestinal canal flora, and residing in the probio in human body intestinal canal can suppress harmful micro-
The growth of pathogenic microorganism such as salmonella etc. in biological and food, probio is in enteron aisle by producing sour, bacteriocin and competing
The acceptor for striving intestinal mucosa plays effect with immunity of organisms is improved.
At present, there is no on market and have simultaneously nourishing liver and kidney, benefiting shrewd head, strengthen immunologic function, anti-curing cancers, beauty,
The like product of the effects such as anti-aging, reduction cholesterol.
The content of the invention
The goal of the invention of the present invention is to provide a kind of preparation method of lycium ruthenicum probiotics tablets, to solve background technology institute
There is no on the market stated and have simultaneously nourishing liver and kidney, benefiting shrewd head, strengthen immunologic function, anti-curing cancers, beauty, anti-aging, drop
The problem of the like product of the effects such as low cholesterol.
Embodiments in accordance with the present invention, there is provided a kind of preparation method of lycium ruthenicum probiotics tablets, the preparation method bag
Include following steps：
S01：With lycium ruthenicum powder, galactooligosaccharide, glucose, microcrystalline cellulose, xylitol, beta carotene and L- apples
Acid is raw material, is granulated after mixing, and particle is screened, and obtains feed particles.
S02：With bifidobacterium lactis V9 powder, Lactobacillus plantarum P-8 bacterium powders and Lactobacillus casei Zhang bacterium powder are raw material, are mixed
Close and probiotic powder is obtained.
S03：The feed particles and the probiotic powder are mixed, compressing tablet raw material is obtained.
S04：The compressing tablet raw material is carried out into compressing tablet using tablet press machine, the lycium ruthenicum probiotics tablets are obtained.
Preferably, the weight proportion of the feed particles raw material is：Lycium ruthenicum powder 50-60 parts, galactooligosaccharide 10-15
Part, glucose 5-10 parts, microcrystalline cellulose 5-10 parts, xylitol 1-10 parts, beta carotene 1-10 parts and L MALIC ACID 1-5 parts.
Preferably, the weight proportion of the probiotic powder raw material is：Bifidobacterium lactis V9 powder 40-60 parts, Lactobacillus plantarum
P-8 bacterium powder 20-40 parts, Lactobacillus casei Zhang bacterium powder 20-40 part.
Preferably, the feed particles and the probiotic powder are (10-200) according to weight proportion:1 mixing, obtains institute
State compressing tablet raw material.
Preferably, the feed particles are granulated using dry granulating machine.
Preferably, the feed particles are the particle of 60-100 mesh.
Preferably, the use pressure of the tablet press machine is 5-30kN.
Preferably, the weight of the lycium ruthenicum probiotics tablets is 100-1000mg.
The preparation method of a kind of lycium ruthenicum probiotics tablets provided from above technical scheme, the present invention, with lycium ruthenicum
Powder, galactooligosaccharide, glucose, microcrystalline cellulose, xylitol, beta carotene and L MALIC ACID are raw material, are made after mixing
Grain, particle is screened, and obtains feed particles.With bifidobacterium lactis V9 powder, Lactobacillus plantarum P-8 bacterium powders and Lactobacillus casei
Zhang bacterium powders are raw material, are mixed to prepare probiotic powder.The feed particles and the probiotic powder are mixed, compressing tablet is obtained former
Material.The compressing tablet raw material is carried out into compressing tablet using tablet press machine, the lycium ruthenicum probiotics tablets are obtained, with the plant of pure natural medicine-food two-purpose
Thing is raw material, tablet made by the probio of the beneficial health of arranging in pairs or groups, without any side effects, is easily absorbed, activity is strong,
Taking convenience, can significantly improve absorbing for lycium ruthenicum nutrient content, strengthen the health-care efficacy of lycium ruthenicum.
Description of the drawings
In order to be illustrated more clearly that the embodiment of the present invention or technical scheme of the prior art, below will be to institute in embodiment
The accompanying drawing that needs are used is briefly described, it should be apparent that, drawings in the following description are only some enforcements of the present invention
Example, for those of ordinary skill in the art, on the premise of not paying creative work, can be being obtained according to these accompanying drawings
Obtain other accompanying drawings.
Fig. 1 is a kind of schematic flow sheet of the preparation method of lycium ruthenicum probiotics tablets provided in an embodiment of the present invention.
Specific embodiment
Below in conjunction with the accompanying drawing in the embodiment of the present invention, the technical scheme in the embodiment of the present invention is carried out clear, complete
Whole description, it is clear that described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.It is based on
Embodiment in the present invention, it is every other that those of ordinary skill in the art are obtained under the premise of creative work is not made
Embodiment, belongs to the scope of protection of the invention.
A kind of schematic flow sheet of the preparation method of lycium ruthenicum probiotics tablets as shown in Figure 1, the embodiment of the present invention is disclosed
A kind of preparation method of lycium ruthenicum probiotics tablets comprise the steps：
S01：With lycium ruthenicum powder, galactooligosaccharide, glucose, microcrystalline cellulose, xylitol, beta carotene and L- apples
Acid is raw material, is granulated after mixing, and particle is screened, and obtains feed particles.
Lycium ruthenicum is sweet, mild-natured, rich in protein, fat, carbohydrate, free amino acid, organic acid, mineral matter, micro unit
The various nutrient contents such as element, alkaloid, vitamin C, B1, B2, calcium, magnesium, copper, zinc, manganese, iron, lead, nickel, cadmium, cobalt, chromium, potassium, sodium.
Jing science detects that its calcium, iron, niacin content are respectively 2.3,4.6,16.7 times of haw matrimony vine, and especially OPC surpasses
Cross blueberry (black fruit lyceum 3690mg/100g containing OPC；Blueberry 330～3380mg/100g containing OPC).This is so far
Till find procyanidin content highest wild fruit, be also maximally effective natural, its effect is VC
20 times, 50 times of VE, the nutrient composition content such as its vitamin, mineral matter is also very abundant, especially containing with removing free radical, antioxygen
Change the natural anthocyanin element of function, medicinal, the significantly larger than common red matrimony vine of health value is described as " soft gold ".
Galactooligosaccharide exists micro in nature in the milk of animal, content is slightly more in breast milk.Galactooligosaccharide is sweet
Taste is purer, calorific value relatively low (7.1J/g), and sugariness is the 20～40% of sucrose, and moisture retention is extremely strong.In the case where pH is neutrallty condition
There is higher heat endurance, heat after 30min at heating 1h or 120 DEG C at 100 DEG C, galactooligosaccharide is without any decomposition.It is oligomeric
With protein, altogether heat Maillard reaction to galactolipin can occur, can be used for the processing of food such as bread, cake etc. of special nature.
The characteristics such as galactooligosaccharide, the physiology of three kinds of compound sugar of oligoisomaltose and FOS are compared,
In three kinds of compound sugar, galactooligosaccharide uniquely can be utilized by the big beneficial bacterium of human body enteral 8.
Galactooligosaccharide is the fabulous nutrient source of the beneficial bacteriums such as Bifidobacterium in human body intestinal canal, Lactobacillus acidophilus and effectively
MF, the digestion and absorption function of human body intestinal canal can be improved.Neonatal digestive function is weaker, so infant
The nutrient content of galactooligosaccharide is all with the addition of in milk powder.
Glucose is biological metabolic indispensable nutriment in vivo.Its oxidation reaction liberated heat is people
The important sources of energy needed for class vital movement.Can be used directly on food, medical industry, go back in printing and dyeing leather industry
Former agent, commonly uses glucose and makees reducing agent in mirror processed industry and the glass liner of a thermos flask silver plating process.It is industrial to be also with glucose in a large number
Material synthesis vitamin C (ascorbic acid).
In pharmaceuticals industry, microcrystalline cellulose is commonly used for adsorbent, suspending agent, diluent, disintegrant to microcrystalline cellulose.It is micro-
Crystalline cellulose is widely used in pharmaceutical preparation, and diluent and adhesive are mainly used as in oral tablet and capsule, not only can use
Dry method direct tablet compressing is can also be used in wet granulation.Also certain lubrication and calving disaggregation, it is highly useful in prepared by tablet.
Xylitol does sweetener, nutritious supplementary pharmaceutical and the auxiliary therapeutical agent of diabetes patient.Xylitol is human body carbohydate metabolism
Intermediate, insulin is lacked in vivo to be affected in the case of glycometabolism, to promote without insulin, and xylitol can also pass through cell
Film, is absorbed by tissue utilization, promotes liver glycogen synthesis, for cell with nutrition and energy, and blood glucose value will not be caused to raise, and eliminates
Diabetes patient take after symptom more than three (food, many drinks, diuresis more), be the sugar of the trophism for being best suitable for patients with diabetes mellitus
Substitute.
Xylitol can promote liver glycogen to synthesize, and blood sugar will not rise, and having to hepatopath improves liver function and AFL
Effect, treat B-mode metastatic hepatitis, chronic hepatitis B and cirrhosis have obvious curative effects, are the reasons of hepatitis concurrent disease patient
Think ancillary drug.
The anti-caries characteristic of xylitol effect in all of sweetener is that xylitol can not be by product in oral cavity preferably first
Cariogenic bacterial fermentation is utilized, and suppresses the generation of streptococcus growth and acid；Secondly when xylitol is chewed, saliva point can be promoted
Secrete, many bacteriums that both can have been rinsed in oral cavity, tooth of saliva, it is also possible to increase at saliva and carious tooth spot basic amino acid and
Ammonia density, while slow down pH value in oral cavity declining, the acidic materials for injuring tooth are neutralized dilution, it is suppressed that bacterium is in tooth table
The absorption in face, so as to reduce the acid etching of tooth, prevents carious tooth and reduces the generation of dental plaque, consolidates tooth.
Xylitol provides energy for human body, synthesizes glycogen, reduces the consumption of fat and the protein in hepatic tissue, makes liver
It is protected and repairs, reduce the generation that ketoboidies is harmful in human body, will not be worry of getting fat because edible.Can be widely used for food
The fields such as product, medicine, light industry.Xylitol compared with common white granulated sugar, with the low advantage of heat --- every gram of xylitol is only
Containing 2.4 caloric heats, the heat few 40% of carbohydrate more most of than other, thus xylitol can be applied to it is various
In diet food, as the substitute of high heat white sugar.
In vivo metabolism is slow for biological xylitol, therefore it will not make insulin fly up or decline, and common sugar is then
Meeting, xylitol is the natural stabiliser of insulin, and food will not increase insulin in blood after using, xylitol also plays stable
The key player of hormone, the horizontal insulin of high target can increase estrogen generation, cause breast cancer also to disturb the health of ovary
Function, insulin resistance is the major reason for producing hormone problem (polycystic ovary syndrome)；So reducing insulin level extremely
Closing the important uneven breast cancer that reduces not only to resisting polycystic ovary syndrome but also to decomposing more other hormones has weight
Want meaning.
In vivo metabolism does not need insulin to participate in xylitol, and raises blood glucose value, and can eliminate diabetes
People more than three (drink, diuresis, many foods more), therefore be sweetener, nutritious supplementary pharmaceutical and the auxiliary therapeutical agent of diabetes patient's safety.
Edible xylitol will not cause carious tooth, go for making the sweetener of the food such as chewing gum, chocolate, hard candy.
Due to its unique function, reconcile with other carbohydrates, alcohols and eat, can be used as the sweetener of food with low sugar content.
Xylitol cool taste, effect more preferably, can be used on the industries such as cold drink, dessert, milk, the coffee of the refreshing heart after frost.
Can be used on the aspects such as health drink, the medicine that wets one's whistle, cough syrup.
In order to healthy, can be used for the substitute that sucrose does in family, to prevent the edible diabetes for excessively causing of sucrose
Obesity.
Xylitol is a kind of polyalcohol, can be used as the moistening regulator of toiletries, to the non-stimulated work of human body skin
With.For example：Cleansing Foam, cosmetic cream, toner etc..
Xylitol has hygroscopicity, preventing caries function, and liquid xylitol has good sweet taste, it is possible to replace
Glycerine makees pipe tobacco, anti-caries toothpaste, the perfuming of collutory, antifreeze NMF etc..
Liquid xylitol can be used in accumulator plate manufacture, stable performance, easily operation, low cost, than glycerine more preferably.
Beta carotene：If people eats daily four parts or more the fruits and vegetables rich in beta carotene, then they suffer from
The probability of heart disease or cancer can be lower.But it is interesting that other researchs are but pointed out deliberately to supplement people's reality of beta carotene
Such disease is more likely suffered from border.Researcher thinks, healthy, reasonable, nutritious diet than solely supplement β-
Carrotene will more effectively to anticancer and heart disease.
Treatment is sensitive to the sun, and there are some researches show the beta carotene of high dose can reduce susceptibility of the people to the sun, especially
It causes dermopathic people to be particularly helpful those due to being exposed to the sun by the sun.They can be appropriate in health care professional
Under guidance, beta carotene is targetedly supplemented, their symptom can at leisure be improved after about several weeks.
L-malic acid is the utilizable form of organism, and it is often equipped with moriamin-s, and (Post operation is important
Nutritional medicine) in, to improve the utilization rate of amino acid, this is weak to Post operation and hepatosis patient is even more important.L-apple
Tartaric acid potassium is that good potassium supplements medicine, and it can keep the diseases such as the water balance of human body, treatment oedema, hypertension and fat generation.
L-malic acid is the good medicine for treating hyperammonemia caused by hepatopathy, especially hepatosis.L-natrium malicum has
1/3 saline taste of salt, can make kidney patient for salt.
L-malic acid is as follows in the purposes of the departments such as food, medicine, daily-use chemical industry：(1) food industry：Be used as processing and
Configuration beverage, alcoholic drink mixed with fruit juice, fruit juice, are also used for the manufacture of candy, jam etc., to food and have an antibacterial antisepsis.Also can be used for acid
Milk fermentation PH is adjusted, except tartrate etc. in wine production；(2) tobacco business：Malic acid derivative (such as esters) can improve
Tobacco flavor；(3) medical industry：Various tablets, syrup be equipped with malic acid can in fruity, and be conducive to absorbing in vivo,
Diffusion；(4) daily-use chemical industry industry：It is good complexing agent, ester agent, for formulation of tooth-paste, the cooperation of net tooth piece, synthetic perfume formula
Deng being also used as the composition of deodorant and detergent.
S02：With bifidobacterium lactis V9 powder, Lactobacillus plantarum P-8 bacterium powders and Lactobacillus casei Zhang bacterium powder are raw material, are mixed
Close and probiotic powder is obtained.
The prebiotic feature of bifidobacterium lactis V9 is：
1) excellent anti-gastrointestinal tract digestive juice tolerance；
2) effective antagonism pathogenic entero becteria, improves the anti-pathogenic infection ability of enteron aisle；Improve gut flora；
3) effectively prevent and alleviate the intestinal irritable syndromes such as diarrhoea, constipation, stomachache, abdominal distension.
Lactobacillus plantarum P-8 bacterium can adjust blood lipid metabolism protection liver；Improve immunity of organisms；Improve gut flora.
Lactobacillus casei Zhang bacterium has significant inhibitory action to enteric pathogenic bacteria；Cellular immunity, body fluid to body
Immunity, intestinal mucosa local immunity have regulatory function；Effect is significantly inhibited to H22 tumor-bearing mice tumour growths, significant drop
Blood fat and oxidation resistance, are effectively increased bifidobacteria intrinsic in enteron aisle.
S03：The feed particles and the probiotic powder are mixed, compressing tablet raw material is obtained.
S04：The compressing tablet raw material is carried out into compressing tablet using tablet press machine, the lycium ruthenicum probiotics tablets are obtained.
Wherein, for a kind of specific embodiment of the preparation method of lycium ruthenicum probiotics tablets may refer to following reality
Apply example：
Embodiment one
S101：Each raw material weight proportioning of soup processed of preparing raw material particle is as follows：50 parts of lycium ruthenicum powder, 10 parts of galactooligosaccharide, Portugal
1 part of 5 parts of grape sugar, 5 parts of microcrystalline cellulose, 1 part of xylitol, 1 part of beta carotene and L MALIC ACID, adopt non-slurry pelletizing after mixing
Machine is granulated, and particle is screened, and obtains the feed particles of 60-100 mesh.
S102：The each raw material weight proportioning of soup processed for preparing probiotic powder is as follows：40 parts of bifidobacterium lactis V9 powder, Lactobacillus plantarum P-
20 parts of 8 20 parts of bacterium powders and Lactobacillus casei Zhang bacterium powder, are mixed to prepare probiotic powder.
S103：It is 10 according to weight proportion by the feed particles and the probiotic powder:1 mixing, obtains compressing tablet raw material.
S104：The compressing tablet raw material is carried out into compressing tablet using the tablet press machine using pressure for 5kN, the lycium ruthenicum benefit is obtained
Raw bacterium piece, the weight of the lycium ruthenicum probiotics tablets is 300mg.
Embodiment two
S201：Each raw material weight proportioning of soup processed of preparing raw material particle is as follows：55 parts of lycium ruthenicum powder, 12 parts of galactooligosaccharide, Portugal
2 parts of 10 parts of grape sugar, 7 parts of microcrystalline cellulose, 5 parts of xylitol, 5 parts of beta carotene and L MALIC ACID, adopt non-slurry pelletizing after mixing
Machine is granulated, and particle is screened, and obtains the feed particles of 60-100 mesh.
S202：The each raw material weight proportioning of soup processed for preparing probiotic powder is as follows：50 parts of bifidobacterium lactis V9 powder, Lactobacillus plantarum P-
30 parts of 8 30 parts of bacterium powders and Lactobacillus casei Zhang bacterium powder, are mixed to prepare probiotic powder.
S203：It is 20 according to weight proportion by the feed particles and the probiotic powder:1 mixing, obtains compressing tablet raw material.
S204：The compressing tablet raw material is carried out into compressing tablet using the tablet press machine using pressure for 15kN, the lycium ruthenicum is obtained
Probiotics tablets, the weight of the lycium ruthenicum probiotics tablets is 500mg.
Embodiment three
S301：Each raw material weight proportioning of soup processed of preparing raw material particle is as follows：60 parts of lycium ruthenicum powder, 15 parts of galactooligosaccharide, Portugal
5 parts of 10 parts of grape sugar, 10 parts of microcrystalline cellulose, 10 parts of xylitol, 10 parts of beta carotene and L MALIC ACID, adopt dry method after mixing
Granulator granulation, particle is screened, and obtains the feed particles of 60-100 mesh.
S302：The each raw material weight proportioning of soup processed for preparing probiotic powder is as follows：60 parts of bifidobacterium lactis V9 powder, Lactobacillus plantarum P-
40 parts of 8 40 parts of bacterium powders and Lactobacillus casei Zhang bacterium powder, are mixed to prepare probiotic powder.
S303：It is 30 according to weight proportion by the feed particles and the probiotic powder:1 mixing, obtains compressing tablet raw material.
S304：The compressing tablet raw material is carried out into compressing tablet using the tablet press machine using pressure for 30kN, the lycium ruthenicum is obtained
Probiotics tablets, the weight of the lycium ruthenicum probiotics tablets is 1000mg.
Example IV
S201：Each raw material weight proportioning of soup processed of preparing raw material particle is as follows：54 parts of lycium ruthenicum powder, 11 parts of galactooligosaccharide, Portugal
1 part of 9 parts of grape sugar, 6 parts of microcrystalline cellulose, 4 parts of xylitol, 4 parts of beta carotene and L MALIC ACID, adopt non-slurry pelletizing after mixing
Machine is granulated, and particle is screened, and obtains the feed particles of 60-100 mesh.
S202：The each raw material weight proportioning of soup processed for preparing probiotic powder is as follows：50 parts of bifidobacterium lactis V9 powder, Lactobacillus plantarum P-
30 parts of 8 30 parts of bacterium powders and Lactobacillus casei Zhang bacterium powder, are mixed to prepare probiotic powder.
S203：It is 200 according to weight proportion by the feed particles and the probiotic powder:1 mixing, obtains compressing tablet former
Material.
S204：The compressing tablet raw material is carried out into compressing tablet using the tablet press machine using pressure for 15kN, the lycium ruthenicum is obtained
Probiotics tablets, the weight of the lycium ruthenicum probiotics tablets is 500mg.
The preparation method of a kind of lycium ruthenicum probiotics tablets provided from above technical scheme, the present invention, with lycium ruthenicum
Powder, galactooligosaccharide, glucose, microcrystalline cellulose, xylitol, beta carotene and L MALIC ACID are raw material, are made after mixing
Grain, particle is screened, and obtains feed particles.With bifidobacterium lactis V9 powder, Lactobacillus plantarum P-8 bacterium powders and Lactobacillus casei
Zhang bacterium powders are raw material, are mixed to prepare probiotic powder.The feed particles and the probiotic powder are mixed, compressing tablet is obtained former
Material.The compressing tablet raw material is carried out into compressing tablet using tablet press machine, the lycium ruthenicum probiotics tablets are obtained, with the plant of pure natural medicine-food two-purpose
Thing is raw material, tablet made by beneficial health probio of arranging in pairs or groups, without any side effects, is easily absorbed, and activity is strong, clothes
With convenient, absorbing for lycium ruthenicum nutrient content can be significantly improved, strengthen the health-care efficacy of lycium ruthenicum.
Those skilled in the art will readily occur to its of the present invention after considering specification and putting into practice invention disclosed herein
Its embodiment.The application is intended to any modification of the present invention, purposes or adaptations, these modifications, purposes or
Person's adaptations follow the general principle of the present invention and including the undocumented common knowledge in the art of the present invention
Or conventional techniques.Description and embodiments are considered only as exemplary, and true scope and spirit of the invention are by following
Claim is pointed out.
It should be appreciated that the precision architecture for being described above and being shown in the drawings is the invention is not limited in, and
And can without departing from the scope carry out various modifications and changes.The scope of the present invention is only limited by appended claim.
Claims (8)
1. a kind of preparation method of lycium ruthenicum probiotics tablets, it is characterised in that the preparation method comprises the steps：
S01：With lycium ruthenicum powder, galactooligosaccharide, glucose, microcrystalline cellulose, xylitol, beta carotene and L MALIC ACID are
Raw material, is granulated after mixing, and particle is screened, and obtains feed particles；
S02：With bifidobacterium lactis V9 powder, Lactobacillus plantarum P-8 bacterium powders and Lactobacillus casei Zhang bacterium powder are raw material, and mixing is made
Obtain probiotic powder；
S03：The feed particles and the probiotic powder are mixed, compressing tablet raw material is obtained；
S04：The compressing tablet raw material is carried out into compressing tablet using tablet press machine, the lycium ruthenicum probiotics tablets are obtained.
2. a kind of preparation method of lycium ruthenicum probiotics tablets according to claim 1, it is characterised in that the feed particles
The weight proportion of raw material is：Lycium ruthenicum powder 50-60 parts, galactooligosaccharide 10-15 parts, glucose 5-10 parts, microcrystalline cellulose 5-
10 parts, xylitol 1-10 parts, beta carotene 1-10 parts and L MALIC ACID 1-5 parts.
3. a kind of preparation method of lycium ruthenicum probiotics tablets according to claim 1, it is characterised in that the probiotic powder
The weight proportion of raw material is：Bifidobacterium lactis V9 powder 40-60 parts, Lactobacillus plantarum P-8 bacterium powder 20-40 parts, Lactobacillus casei
Zhang bacterium powder 20-40 parts.
4. a kind of preparation method of lycium ruthenicum probiotics tablets according to claim 1, it is characterised in that the feed particles
With the probiotic powder according to weight proportion be (10-200):1 mixing, obtains the compressing tablet raw material.
5. a kind of preparation method of lycium ruthenicum probiotics tablets according to claim 1, it is characterised in that the feed particles
Granulated using dry granulating machine.
6. a kind of preparation method of lycium ruthenicum probiotics tablets according to claim 1, it is characterised in that the feed particles
For the particle of 60-100 mesh.
7. the preparation method of a kind of lycium ruthenicum probiotics tablets according to claim 1, it is characterised in that the tablet press machine
The use of pressure is 5-30kN.
8. a kind of preparation method of lycium ruthenicum probiotics tablets according to claim 1, it is characterised in that the lycium ruthenicum benefit
The weight of raw bacterium piece is 100-1000mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611130168.XA CN106616602A (en) | 2016-12-09 | 2016-12-09 | Preparation method of black Chinese wolfberry fruit probiotic tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611130168.XA CN106616602A (en) | 2016-12-09 | 2016-12-09 | Preparation method of black Chinese wolfberry fruit probiotic tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106616602A true CN106616602A (en) | 2017-05-10 |
Family
ID=58825719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611130168.XA Pending CN106616602A (en) | 2016-12-09 | 2016-12-09 | Preparation method of black Chinese wolfberry fruit probiotic tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106616602A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107568553A (en) * | 2017-08-25 | 2018-01-12 | 上海应用技术大学 | A kind of matrimony vine probiotics effervescent tablet and preparation method thereof |
| WO2019002421A1 (en) * | 2017-06-27 | 2019-01-03 | Rottapharm Spa | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
| CN112616987A (en) * | 2021-01-06 | 2021-04-09 | 新疆黑果枸杞生物科技有限公司 | Lycium ruthenicum Murr essence tablet tabletting candy and preparation method thereof |
| CN113812622A (en) * | 2021-09-10 | 2021-12-21 | 盛尚杞美(宁夏)生物科技开发有限公司 | Chinese wolfberry tablet for improving human intestinal flora and preparation method thereof |
| CN114073313A (en) * | 2021-11-19 | 2022-02-22 | 北京局气网络技术有限公司 | Compound oligosaccharide active bacterium medlar tablet and preparation method thereof |
| RU2780618C2 (en) * | 2017-06-27 | 2022-09-28 | Роттафарм Спа | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102204679A (en) * | 2011-06-16 | 2011-10-05 | 高杰 | Quadruple bacterial tablets and preparation method thereof |
| CN102813739A (en) * | 2011-06-10 | 2012-12-12 | 冯丽花 | Longevity life-prolonging tablet |
| CN104055936A (en) * | 2014-07-11 | 2014-09-24 | 郭海涛 | Method for preparing lycium barbarum tablet |
| CN104382047A (en) * | 2014-12-03 | 2015-03-04 | 青岛根源生物技术集团有限公司 | Gynostemma pentaphylla probiotic chewable tablet and preparation method thereof |
| CN104719887A (en) * | 2013-12-23 | 2015-06-24 | 无锡伟康生物科技有限公司 | Composite probiotic powder for conditioning intestinal tract flora |
-
2016
- 2016-12-09 CN CN201611130168.XA patent/CN106616602A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813739A (en) * | 2011-06-10 | 2012-12-12 | 冯丽花 | Longevity life-prolonging tablet |
| CN102204679A (en) * | 2011-06-16 | 2011-10-05 | 高杰 | Quadruple bacterial tablets and preparation method thereof |
| CN104719887A (en) * | 2013-12-23 | 2015-06-24 | 无锡伟康生物科技有限公司 | Composite probiotic powder for conditioning intestinal tract flora |
| CN104055936A (en) * | 2014-07-11 | 2014-09-24 | 郭海涛 | Method for preparing lycium barbarum tablet |
| CN104382047A (en) * | 2014-12-03 | 2015-03-04 | 青岛根源生物技术集团有限公司 | Gynostemma pentaphylla probiotic chewable tablet and preparation method thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019002421A1 (en) * | 2017-06-27 | 2019-01-03 | Rottapharm Spa | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
| US11234997B2 (en) | 2017-06-27 | 2022-02-01 | Rottapharm Spa | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
| RU2780618C2 (en) * | 2017-06-27 | 2022-09-28 | Роттафарм Спа | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
| AU2018293307B2 (en) * | 2017-06-27 | 2023-09-21 | Rottapharm Spa | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
| EP4241855A3 (en) * | 2017-06-27 | 2023-10-25 | Rottapharm SPA | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments |
| CN107568553A (en) * | 2017-08-25 | 2018-01-12 | 上海应用技术大学 | A kind of matrimony vine probiotics effervescent tablet and preparation method thereof |
| CN112616987A (en) * | 2021-01-06 | 2021-04-09 | 新疆黑果枸杞生物科技有限公司 | Lycium ruthenicum Murr essence tablet tabletting candy and preparation method thereof |
| CN113812622A (en) * | 2021-09-10 | 2021-12-21 | 盛尚杞美(宁夏)生物科技开发有限公司 | Chinese wolfberry tablet for improving human intestinal flora and preparation method thereof |
| CN114073313A (en) * | 2021-11-19 | 2022-02-22 | 北京局气网络技术有限公司 | Compound oligosaccharide active bacterium medlar tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109043548B (en) | Composition, product for maintaining beauty and keeping young and delaying senescence and application | |
| CN106616602A (en) | Preparation method of black Chinese wolfberry fruit probiotic tablets | |
| CN102224891B (en) | Sugar alcohol honey apple jam and preparation method thereof | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| CN104622922A (en) | Horseradish tree leaf tablet and preparation method thereof | |
| CN105249452A (en) | Fruit and vegetable enzyme powder with weight reducing function and preparation method thereof | |
| CN102813115A (en) | Compound active cosmetic collagen powder | |
| CN103976023A (en) | Okra yogurt beverage and preparation method thereof | |
| CN104855967A (en) | Non-whole nutrient formula food for patients having obesity or fat-reducing surgery | |
| CN111194841A (en) | Functional spirulina protein peptide drink capable of improving immunity and improving sleep quality | |
| CN103751327A (en) | Zinc gluconate VC (Vitamin C) effervescent tablet | |
| CN105028868A (en) | Black garlic, black onion and black soybean peptide chewable tablet and preparation method thereof | |
| CN101243824A (en) | Green pawpaw mastication tablet and producing method thereof | |
| CN104738624A (en) | Nutritional health-care food for neurasthenia, amnesia and insomnia | |
| CN107173656A (en) | A kind of Chinese medicine fruits and vegetables probiotics fermented beverage and preparation method thereof | |
| CN101099526B (en) | Ginseng flower health tea drink and its preparing method | |
| CN101449824A (en) | Blueberry rose-hip bee pollen food | |
| CN105341300A (en) | Health-care candies suitable for children to eat | |
| CN104839670A (en) | Specific endowment constitution medical formula food | |
| CN103271353B (en) | Liver protecting and health care composition and preparation method thereof | |
| CN102715606A (en) | Beverage | |
| CN115486541B (en) | Herbal probiotic composition with whitening effect and preparation method thereof | |
| CN108634177A (en) | A kind of health type high protein rice flour | |
| CN101861990B (en) | Pearl vitamin C buccal tablets | |
| CN107373674A (en) | Alimentation composition and its application after a kind of oncotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |